Screener
BridgeBio Pharma BBIO Reportable Segment — Cost of Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Cost of revenues: | ||
| Cost of goods sold | 7,732 | 2,034 |
| Cost of license, services, and royalty revenue | 2,207 | 605 |
| Total cost of revenues | 9,939 | 2,639 |
| Research and development by significant program: | ||
| Acoramidis for the treatment of ATTR-CM and primary prevention in asymptomatic carriers of a pathogenic TTR variant | 31,391 | 24,392 |
| Infigratinib for achondroplasia and hypochondroplasia | 35,533 | 27,934 |
| BBP-418 for LGMD2I/R9 | 15,608 | 14,209 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's reportable segment — cost of revenue?
- BridgeBio Pharma (BBIO) reported reportable segment — cost of revenue of $9.94M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — cost of revenue changed year-over-year?
- BridgeBio Pharma's reportable segment — cost of revenue increased by 276.6% year-over-year, from $2.64M to $9.94M.
- What does reportable segment — cost of revenue mean?
- Includes the direct costs attributable to the production and delivery of products sold within the reportable segment. This encompasses manufacturing, logistics, and direct supply chain expenses.
Ask your AI about BridgeBio Pharma's reportable segment — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude